» Articles » PMID: 37296849

Unraveling the Role of Epithelial-Mesenchymal Transition in Adenoid Cystic Carcinoma of the Salivary Glands: A Comprehensive Review

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Jun 10
PMID 37296849
Authors
Affiliations
Soon will be listed here.
Abstract

Salivary adenoid cystic carcinoma (SACC) is considered a challenging malignancy; it is characterized by a slow-growing nature, yet a high risk of recurrence and distant metastasis, presenting significant hurdles in its treatment and management. At present, there are no approved targeted agents available for the management of SACC and systemic chemotherapy protocols that have demonstrated efficacy remain to be elucidated. Epithelial-mesenchymal transition (EMT) is a complex process that is closely associated with tumor progression and metastasis, enabling epithelial cells to acquire mesenchymal properties, including increased mobility and invasiveness. Several molecular signaling pathways have been implicated in the regulation of EMT in SACC, and understanding these mechanisms is crucial to identifying new therapeutic targets and developing more effective treatment approaches. This manuscript aims to provide a comprehensive overview of the latest research on the role of EMT in SACC, including the molecular pathways and biomarkers involved in EMT regulation. By highlighting the most recent findings, this review offers insights into potential new therapeutic strategies that could improve the management of SACC patients, especially those with recurrent or metastatic disease.

Citing Articles

Effect of silencing Ras homolog family member C on proliferation, invasion, and migration of salivary adenoid cystic carcinoma.

Yu W, Zhao P, Shao Y, Xu Y, Xu J, Xie L Hua Xi Kou Qiang Yi Xue Za Zhi. 2024; 42(6):723-734.

PMID: 39610069 PMC: 11669934. DOI: 10.7518/hxkq.2024.2024092.


Transcription Factors and Markers Related to Epithelial-Mesenchymal Transition and Their Role in Resistance to Therapies in Head and Neck Cancers.

Pawlicka M, Gumbarewicz E, Blaszczak E, Stepulak A Cancers (Basel). 2024; 16(7).

PMID: 38611032 PMC: 11010970. DOI: 10.3390/cancers16071354.

References
1.
de Freitas Silva B, Yamamoto-Silva F, Pontes H, Dos Santos Pinto Junior D . E-cadherin downregulation and Twist overexpression since early stages of oral carcinogenesis. J Oral Pathol Med. 2013; 43(2):125-31. DOI: 10.1111/jop.12096. View

2.
Cantu G . Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A: from aetiopathogenesis to diagnosis. Acta Otorhinolaryngol Ital. 2021; 41(3):206-214. PMC: 8283400. DOI: 10.14639/0392-100X-N1379. View

3.
Denaro M, Navari E, Ugolini C, Seccia V, Donati V, Casani A . A microRNA signature for the differential diagnosis of salivary gland tumors. PLoS One. 2019; 14(1):e0210968. PMC: 6347363. DOI: 10.1371/journal.pone.0210968. View

4.
Xu L, Zhao F, Yang W, Chen C, Du Z, Fu M . MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma. Int J Oncol. 2019; 54(5):1579-1590. PMC: 6438425. DOI: 10.3892/ijo.2019.4754. View

5.
Chae Y, Chung S, Davis A, Carneiro B, Chandra S, Kaplan J . Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 2015; 6(35):37117-34. PMC: 4741919. DOI: 10.18632/oncotarget.5076. View